Literature DB >> 22460069

RAGE processing in chronic airway conditions: involvement of Staphylococcus aureus and ECP.

Koen Van Crombruggen1, Gabriele Holtappels, Natalie De Ruyck, Lara Derycke, Peter Tomassen, Claus Bachert.   

Abstract

BACKGROUND: The receptor for advanced glycation end products (RAGE) is a multiligand receptor that exists as a membrane-bound (mRAGE) form and a soluble (sRAGE) form. RAGE is reported to play a role in diverse pathologies including lower airway conditions, but the exact mechanism of action remains poorly understood. In the upper airways, the involvement of RAGE remains completely unexplored.
OBJECTIVE: To investigate the involvement of RAGE in the human upper airway conditions chronic rhinosinusitis without nasal polyps (CRSsNP) and chronic rhinosinusitis with nasal polyps (CRSwNP).
METHODS: Protein levels of sRAGE, mRAGE, IL-5, and eosinophil cationic protein (ECP) were quantitatively assessed in inflamed tissue of CRSsNP and CRSwNP patients. Nasal tissue of subjects without disease served as control. Ex vivo human sinonasal tissue stimulation assays were used to assess the effect of Staphylococcus aureus and ECP on sRAGE processing.
RESULTS: sRAGE protein levels were higher in CRSsNP tissue, whereas mRAGE protein levels were lower than in controls. In CRSwNP patients, both tissue sRAGE and mRAGE protein levels were reduced. Low tissue sRAGE protein concentrations were associated with high IL-5 and ECP protein levels. In vitro, S aureus induced the release of sRAGE from the tissue, while ECP was shown to be implicated in the breakdown of free sRAGE.
CONCLUSIONS: We demonstrate for the first time that RAGE protein is highly expressed in human upper airways under normal physiology and that it is subject to differential processing in CRSsNP and CRSwNP, identifying S aureus and ECP as novel and crucial players in this process.
Copyright © 2012 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22460069     DOI: 10.1016/j.jaci.2012.02.021

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  7 in total

1.  Involvement of the extracellular matrix proteins periostin and tenascin C in nasal polyp remodeling by regulating the expression of MMPs.

Authors:  Kun Du; Min Wang; Nan Zhang; Pei Yu; Ping Wang; Ying Li; Xiangdong Wang; Luo Zhang; Claus Bachert
Journal:  Clin Transl Allergy       Date:  2021-09-06       Impact factor: 5.657

Review 2.  Damage-associated molecular patterns and their receptors in upper airway pathologies.

Authors:  Koen Van Crombruggen; Fenila Jacob; Nan Zhang; Claus Bachert
Journal:  Cell Mol Life Sci       Date:  2013-05-15       Impact factor: 9.261

Review 3.  Differential expression and role of S100 proteins in chronic rhinosinusitis.

Authors:  Jorgen S Sumsion; Abigail Pulsipher; Jeremiah A Alt
Journal:  Curr Opin Allergy Clin Immunol       Date:  2020-02

4.  Expression of the receptor for advanced glycation end products, a target for high mobility group box 1 protein, and its role in chronic recalcitrant rhinosinusitis with nasal polyps.

Authors:  Karolina Dzaman; Miroslaw J Szczepanski; Marta Molinska-Glura; Antoni Krzeski; Mariola Zagor
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2014-12-12       Impact factor: 4.291

5.  Suppression of cytokine release by fluticasone furoate vs. mometasone furoate in human nasal tissue ex-vivo.

Authors:  Nan Zhang; Koen Van Crombruggen; Gabriele Holtappels; Feng Lan; Michail Katotomichelakis; Luo Zhang; Petra Högger; Claus Bachert
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

Review 6.  Pathophysiology of chronic rhinosinusitis, pharmaceutical therapy options.

Authors:  Claus Bachert; Gabriële Holtappels
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2015-12-22

Review 7.  Roles of Exosomes in Chronic Rhinosinusitis: A Systematic Review.

Authors:  Karolina Dżaman; Katarzyna Czerwaty
Journal:  Int J Mol Sci       Date:  2022-09-25       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.